– USA, FL – ERBA Diagnostics, Inc. (NYSE: ERB), a fully integrated in vitro diagnostics company, announced today that Hayden Jeffreys was appointed to the Company’s Board of Directors. Mr. Jeffreys has twenty (20) years of experience in the clinical diagnostics industry, with specialization in the molecular diagnostic and blood bank fields. Mr. Jeffreys currently serves as the Commercial Director for the Molecular Diagnostics Division and as the Head of the Business Development and Strategy for ERBA Diagnostics Mannheim GmbH, which beneficially owns, directly or indirectly, approximately 83.3% of the outstanding shares of the Company’s common stock. Prior to joining ERBA Diagnostics Mannheim GmbH, Mr. Jeffreys served in a variety of positions for companies involved in the diagnostics industry, including: Commercial Director for Lumora Ltd., a molecular diagnostic product and technology development company, from 2012 through 2015; Divisional Director Diagnostic Products for Lab21 Healthcare, a leading manufacturer of infectious disease, blood banking products and molecular diagnostic services, from 2008 through 2012; and, prior thereto, various positions at Invitron Ltd; Kronus Inc. and Gen-Probe UK Ltd.
The company also announced that it has entered into an amendment to employment agreement with Mohan Gopalkrishnan, the Company’s Chief Executive Officer, which extended Mr. Mohan’s term of employment for seven (7) months, such that his contract term will now expire on December 31, 2016.
About ERBA Diagnostics, Inc.
ERBA Diagnostics, Inc. (NYSE MKT:ERB), is a fully integrated in vitro diagnostics company, offering a comprehensive suite of clinical testing products throughout the U.S. and emerging markets. The Company serves as a one-stop shop for the testing needs of the growing number of smaller hospitals, reference labs, and physician clinics. ERBA Diagnostics’ line of proprietary and automated instruments, test kits, and reagents provide customers with autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
